

26 October 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

Scrip Code: 543064

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Intimation of Board Meeting of the Company

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that a meeting of the Board of Directors of the Company will be held on **Friday, 6 November 2026**, *inter alia*, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half-year ended 30 September 2026.

Further, in continuation to our letter dated 28 September 2026 regarding closure of Trading Window for dealing in the shares of the Company for Designated Persons and their immediate relatives, the Trading Window shall remain closed until 9 November 2026.

Kindly take the above information record.

Thanking you

Yours faithfully,

For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

**Sisira
Kumar
Mishra**
Digitally signed
by Sisira Kumar
Mishra
Date: 2026.10.26
17:35:37 +05'30'

Sisir K. Mishra

Company Secretary & Compliance Officer

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

